The previous monarcHER trial demonstrated that trastuzumab plus abemaciclib plus fulvestrant significantly improved PFS in patients with HR‐positive, HER2‐positive advanced breast cancer compared with trastuzumab plus chemotherapy [73]. Here, ERBB2 is linked to breast carcinoma.